In the last decade, the HIV prevention field has witnessed a distinct shift, with emphasis on biomedical strategies to supplement behavioral interventions. One of these approaches is the use of preexposure prophylaxis (PrEP), co-formulated antiretroviral medications taken to reduce the risk of HIV infection.
Despite the commonly held belief that marijuana suppresses aggression, many cross-sectional and longitudinal surveys find positive associations between marijuana use and intimate partner violence (IPV).
The prevention of HIV acquisition has been transformed over the last decade with the introduction of pre-exposure prophylaxis (PrEP), in which at-risk HIV uninfected individuals take antiretroviral medications daily to prevent infection.
To maximize its prevention potential, the public health impact of pre-exposure prophylaxis (PrEP) requires an approach that will lead to: 1) large-scale adoption among eligible populations and 2) identification of current gaps among prescribers.